financetom
Business
financetom
/
Business
/
Orla Mining Up 0.25% In US Premarket As Confirms Gold Mineralization At North Bullion Deposit, Defines New Drill Targets Across South Railroad Project
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Orla Mining Up 0.25% In US Premarket As Confirms Gold Mineralization At North Bullion Deposit, Defines New Drill Targets Across South Railroad Project
Apr 4, 2024 4:48 AM

07:15 AM EDT, 04/04/2024 (MT Newswires) -- Orla Mining Ltd. ( ORLA ) on Thursday said exploration at the South Railroad project confirmed strong Carlin-type mineralization at the North Bullion sulphide deposit and defined new drill targets across the project.

In its most recent update, Orla reported strong drill results from the North Bullion deposit, including 3.24 g/t gold over 51.8 meters. Assay results confirmed positive gold values consistent with historical assays, leading to a revision of the geological model and identification of targets for the 2024 drilling extensions of the deposit.

Orla's 2023 program focused on testing exploration targets across the South Railroad property returned assay results justifying follow-up exploration drilling in 2024 on the extension of the North Bullion and Jasperoid Wash mineralized zones.

"Since our acquisition of the South Railroad project in August 2022, we've made tremendous progress in our exploration efforts on the South Carlin Trend," said Sylvia Guerard, Orla's senior vice president of exploration. "With expanded 2024 program planned, we aim to drill over 22,000 metres, with the goal of unlocking further value from this exceptional project."

Orla plans to increase its exploration budget by $3.0 million, subject to closing of the Contact Gold acquisition, boosting total 2024 exploration spend to $13.0 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Olaplex Holdings Names Catherine Dunleavy CFO, COO
Olaplex Holdings Names Catherine Dunleavy CFO, COO
Jul 11, 2024
08:55 AM EDT, 07/11/2024 (MT Newswires) -- Olaplex Holdings ( OLPX ) said Thursday that it has appointed Catherine Dunleavy as its chief financial officer and chief operating officer, effective Aug. 13. Dunleavy most recently served as president of Away, Olaplex ( OLPX ) said. Olaplex ( OLPX ) said it has also appointed Katie Gohman as its chief marketing...
ChargePoint Holdings Appoints CFO, Chief Development Officer; New Director Joins Board's Audit Committee
ChargePoint Holdings Appoints CFO, Chief Development Officer; New Director Joins Board's Audit Committee
Jul 11, 2024
08:46 AM EDT, 07/11/2024 (MT Newswires) -- ChargePoint Holdings ( CHPT ) said Thursday it has appointed Mansi Khetani as chief financial officer and Ash Chowdappa as chief development officer for software, effective earlier this week. Khetani had been the company's interim CFO since November, while Chowdappa was previously the senior vice president of software at HPE Aruba Networks. Additionally,...
What's Going On With FuelCell Energy Stock Today?
What's Going On With FuelCell Energy Stock Today?
Jul 11, 2024
FuelCell Energy Inc ( FCEL ) shares are trading higher. The company on Thursday highlighted a significant Korean market expansion milestone and provided some details from a recent event in Seoul. What Happened: FuelCell said it recently held an event in Seoul, reinforcing the company’s commitment to the Korean market and highlighting how its two differentiated carbonate and solid oxide...
Abeona Therapeutics Partners with Beacon Therapeutics to Develop Ophthalmic Gene Therapies
Abeona Therapeutics Partners with Beacon Therapeutics to Develop Ophthalmic Gene Therapies
Jul 11, 2024
08:46 AM EDT, 07/11/2024 (MT Newswires) -- Abeona Therapeutics ( ABEO ) said Thursday it entered into an exclusive agreement with Beacon Therapeutics to evaluate its patented AAV204 capsid to potentially develop and market gene therapies for specific ophthalmic conditions. Under the deal, Beacon Therapeutics has secured a 12-month evaluation period for AAV204 capsid for select ophthalmology indications and holds...
Copyright 2023-2026 - www.financetom.com All Rights Reserved